Skip to main content
SpringerLink
Log in

Zofenopril preferred option at acceptable cost in LVD

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Survival of Myocardial Infarction Long-term Evaluation 4

Reference

  • Borghi C, et al. Cost Effectiveness of Zofenopril in the Treatment of Patients with Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: A Post-Hoc Analysis of the SMILE-4 Study. 63rd Annual Scientific Session of the American College of Cardiology : abstr. 1225-228, 29 Mar 2014.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zofenopril preferred option at acceptable cost in LVD. PharmacoEcon Outcomes News 703, 9 (2014). https://doi.org/10.1007/s40274-014-1269-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1269-1

Search

Navigation